Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years. [electronic resource]
Producer: 20120705Description: 13-21 p. digitalISSN:- 2046-4924
- Anti-Asthmatic Agents -- administration & dosage
- Antibodies, Anti-Idiotypic -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Asthma -- drug therapy
- Child
- Cost-Benefit Analysis
- Drug Therapy, Combination
- Glucocorticoids -- therapeutic use
- Humans
- Models, Economic
- Multicenter Studies as Topic
- Omalizumab
- Quality of Life
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- Severity of Illness Index
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.